Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?

Literature DB >> 18591894

Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?

L Bartalena¹, C Marcocci, A Lai, M L Tanda.

Abstract

Entities: Disease

Mesh：

Year: 2008 PMID： 18591894 DOI： 10.1007/BF03346411

Source DB: PubMed Journal: J Endocrinol Invest ISSN： 0391-4097 Impact factor: 4.256

× No keyword cloud information.

29 in total

Review 1. Graves' disease.

Authors: A P Weetman
Journal: N Engl J Med Date: 2000-10-26 Impact factor: 91.245

2. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment.

Authors: P Vitti; T Rago; L Chiovato; S Pallini; F Santini; E Fiore; R Rocchi; E Martino; A Pinchera
Journal: Thyroid Date: 1997-06 Impact factor: 6.568

Review 3. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism.

Authors: C Marcocci; L Bartalena; F Bogazzi; G Bruno-Bossio; A Pinchera
Journal: Thyroid Date: 1992 Impact factor: 6.568

4. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine.

Authors: F Azizi; L Ataie; M Hedayati; Y Mehrabi; F Sheikholeslami
Journal: Eur J Endocrinol Date: 2005-05 Impact factor: 6.664

5. Preventing Graves' ophthalmopathy.

Authors: W M Wiersinga
Journal: N Engl J Med Date: 1998-01-08 Impact factor: 91.245

6. The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy.

Authors: D H Khoo; S C Ho; L L Seah; K S Fong; E S Tai; S P Chee; P H Eng; S E Aw; A C Fok
Journal: Thyroid Date: 1999-12 Impact factor: 6.568

7. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.

Authors: Mario Salvi; Guia Vannucchi; Irene Campi; Nicola Currò; Davide Dazzi; Simona Simonetta; Paola Bonara; Stefania Rossi; Clara Sina; Claudio Guastella; Roberto Ratiglia; Paolo Beck-Peccoz
Journal: Eur J Endocrinol Date: 2007-01 Impact factor: 6.664

Review 8. Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism?

Authors: Peter Laurberg
Journal: Eur J Endocrinol Date: 2006-12 Impact factor: 6.664

9. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.

Authors: L Bartalena; C Marcocci; F Bogazzi; L Manetti; M L Tanda; E Dell'Unto; G Bruno-Bossio; M Nardi; M P Bartolomei; A Lepri; G Rossi; E Martino; A Pinchera
Journal: N Engl J Med Date: 1998-01-08 Impact factor: 91.245

10. Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of graves' ophthalmopathy.

Authors: Mariacarla Moleti; Filiberto Mattina; Ignazio Salamone; Maria Antonia Violi; Carmelo Nucera; Sergio Baldari; Maria Grazia Lo Schiavo; Concetto Regalbuto; Francesco Trimarchi; Francesco Vermiglio
Journal: Thyroid Date: 2003-07 Impact factor: 6.568

4 in total

1. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study.

Authors: Annamaria De Bellis; Giovanni Conzo; Gilda Cennamo; Elena Pane; Giuseppe Bellastella; Caterina Colella; Assunta Dello Iacovo; Vanda Amoresano Paglionico; Antonio Agostino Sinisi; Jack R Wall; Antonio Bizzarro; Antonio Bellastella
Journal: Endocrine Date: 2011-11-16 Impact factor: 3.633